Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment history, Novartis International AG
Release Date: 2010-04-13
Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).Data from the two-year FREEDOMS study showed that Gilenia 0.5 mg reduced annual relapse rates (ARR) by 62% for treatment naïve patients compared to placebo. For patients previously receiving other treatments, the annual relapse rates were reduced by 44%. In addition, at two years Gilenia delayed the progression of disability by 30% for patients on 0.5 mg compared to placebo (according to a study by Kappos L. et al. on Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis).
"These findings reinforce the potential for Gilenia to be a breakthrough therapy option for physicians and people with relapsing forms of MS," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "The data demonstrate the effectiveness of Gilenia irrespective of treatment history, and further support both the sustained efficacy of Gilenia over two years and the potential benefits of switching from interferon beta-1a, a currently approved MS therapy, to Gilenia."
| Type: | NORMAL |
| Company: | Novartis International AG |
| Country: | 瑞士 |